50 high-performance-computing-postdoc Fellowship positions at University of Birmingham in United Kingdom
Sort by
Refine Your Search
-
Job Description Position Details School of Computer Science Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with
-
potential progression once in post to £48,149 Grade: 7 Full Time, Fixed Term contract up to August 2028 Closing date: 15th July 2025 Background We are seeking an innovative Research Fellow in Computational
-
Job Description Position Details School of Computer Science Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,636 to £46,049 with
-
. in Computer Science, Machine Learning, Computational Linguistics, Artificial Intelligence or a related field High level analytical capability Ability to communicate complex information clearly Fluency
-
dedicated to open, inclusive and inspiring research spaces for academics and their collaborators. In addition, the University of Birmingham offers exceptional High Performance Computing facilities, including
-
Birmingham Professional programme which provides all professional services staff with development opportunities and the encouragement to reach their full potential. With almost 5,000 professional services jobs
-
will lead a project funded by the Grace Kelly Cancer Childhood Trust to test the performance of this tool, further develop and improve the tool, increase the number and range of tumours the programme
-
administer new play-based measures of executive functioning. The Research Fellow will lead on project initiation, participant recruitment, data collection, data management and analysis, report writing
-
of the responsibilities outlined below. Perform research and collect data in the specified area to a high level of competency and quality Maintain a high level of knowledge of the immediate and surrounding literature
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor